Related Experiment Video

Updated: May 6, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Emerging options for the management of non-small cell lung cancer

Daniel Binder1, Karin Hegenbarth

  • 1Department of Hematology, Oncology, and Tumor Immunology, HELIOS Klinikum Berlin-Buch, Berlin, Germany.

Clinical Medicine Insights. Oncology
|November 2, 2013
PubMed

Insights

This review covers key driver mutations in non-small cell lung cancer (NSCLC). It details progress in targeted therapies like epidermal growth factor receptor (EGFR) inhibitors and others for advanced lung cancer treatment.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Lung cancer is a major global health concern, with non-small cell lung cancer (NSCLC) comprising the majority of cases.
  • Effective systemic tumor control is crucial for improving outcomes in advanced NSCLC.
  • While epidermal growth factor receptor (EGFR) targeted therapies are established, other treatment modalities require further investigation.

Purpose of the Study:

  • To review significant driver mutations in NSCLC.
  • To summarize current advancements in targeted therapies for NSCLC.
  • To discuss the status of EGFR-directed therapy, anaplastic lymphoma kinase (ALK)-directed agents, antiangiogenic therapy, and mesenchymal-epithelial transition factor (MET) inhibitors.

Main Methods:

  • Literature review of recent studies and clinical research.
  • Analysis of therapeutic strategies for NSCLC.
  • Focus on targeted therapies and their efficacy.

Main Results:

  • Identified key driver mutations influencing NSCLC progression.
  • Summarized efficacy and status of EGFR inhibitors, ALK inhibitors, antiangiogenic therapy, and MET inhibitors.
  • Highlighted ongoing research into novel therapeutic agents.

Conclusions:

  • Targeted therapies, including EGFR, ALK, and MET inhibitors, represent significant progress in NSCLC treatment.
  • Further research is essential to elucidate the full potential of existing and emerging therapies for advanced NSCLC.
Keywords:
NSCLCchemotherapylung cancertargeted therapy

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

683

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K